Anti-alpha-synuclein program for MSA (acquired by AC Immune)
Multiple System Atrophy (MSA)
Phase 1Acquired/Partnered
Key Facts
About AFFiRiS
AFFiRiS is an Austrian biotechnology company pioneering a vaccine-like immunotherapy platform, AFFITOME®, to treat chronic diseases by targeting pathological proteins. Its most advanced programs target alpha-synuclein for Parkinson's disease and PCSK9 for hypercholesterolemia, with multiple assets having reached Phase 1 clinical trials. The company operates as a private entity, advancing its pipeline through strategic partnerships and out-licensing deals, such as the acquisition of its alpha-synuclein programs by AC Immune in 2021.
View full company profileTherapeutic Areas
Other Multiple System Atrophy (MSA) Drugs
| Drug | Company | Phase |
|---|---|---|
| HB-adMSCs for Multiple System Atrophy | Hope Biosciences | Phase 1/2 |
| anle138b | Modag | Phase 1/2 |
| YA-101 | Yoda Therapeutics | Phase 2 |
| Novel Neuroscience Candidate | Teva Pharmaceutical Industries | Phase 2 |
| Anti-alpha-synuclein Oligomer mAb | bioarctic-ab | Discovery |
| ATH434 | Alterity Therapeutics | Phase 2 |